摘要
目的探讨新辅助化疗结合手术治疗晚期卵巢癌的近期与远期疗效。方法回顾性分析我院2018年1月—2019年1月期间收治的晚期卵巢癌患者91例,根据不同治疗方法将其分为单纯手术组(44例)和联合治疗组(47例)。单纯手术组患者仅采用卵巢肿瘤细胞减灭术治疗,联合治疗组采用紫杉醇、卡铂方案结合卵巢肿瘤细胞减灭术治疗。比较两组患者手术相关指标,治疗前后血清糖类抗原125(CA125)、人附睾蛋白4(HE4)水平变化,近期疗效及3年随访生存情况。结果联合治疗组患者手术时间短于单纯手术组,术中失血量少于单纯手术组(P<0.05)。联合治疗组病灶理想减灭率(72.34%)高于单纯手术组(45.45%),脏器切除率(8.51%)低于单纯手术组(25.00%),临床总有效率(74.47%)高于单纯手术组(52.27%),差异均有统计学意义(P<0.05)。治疗后,两组患者血清CA125、HE4水平均较治疗前明显降低(P<0.05),且联合治疗组血清CA125、HE4水平均显著低于单纯手术组(P<0.001)。联合治疗组中位生存时间为31.68(26.23~37.13)个月,单纯手术组为29.25(24.32~34.85)个月,差异无统计学意义(P>0.05)。联合治疗组1、2、3年生存率分别为95.74%、72.34%、44.68%,单纯手术组分别为88.64%、61.36%、38.64%,差异无统计学意义(P>0.05)。结论新辅助化疗结合手术治疗可有效减少晚期卵巢癌患者的手术时间,降低术中失血量及脏器切除率,提高病灶减灭率及近期疗效,但对远期生存情况无明显改善。
Objective To investigate the short-term and long-term efficacy of neoadjuvant chemotherapy combined with cytoreductive surgery in the treatment of advanced ovarian cancer.Methods A total of 91 patients with advanced ovarian cancer treated in our hospital between January 2018 and January 2019 were analyzed retrospectively.According to different treatment methods,the patients were divided into operation group(44 cases) and combined treatment group(47 cases).Patients in the operation group were only treated with ovarian cytoreductive surgery,while those in the combined treatment group were treated with paclitaxel and carboplatin combined with ovarian cytoreductive surgery.Compare the operationrelated indexes,changes of serum levels of carbohydrate antigen 125(CA125) and human epididymal protein 4(HE4) before and after treatment,short-term efficacy and 3 years of survival between the two groups.Results The operation time in the combined treatment group was shorter than in the operation group,and the intraoperative blood loss was less than in the operation group(P0.05).The 1-,2-,3-year survival rate of the combined treatment group was respectively 95.74%,72.34%,44.68%,and those of the operation group was respectively 88.64%,61.36%,38.64%,and there were no statistical differences between the two groups(P>0.05).Conclusion Neoadjuvant chemotherapy combined with cytoreductive surgery can effectively shorten the operation time,reduce intraoperative blood loss and organ resection rate,and improve the lesion reduction rate and short-term curative effect of advanced ovarian cancer patients.However,the combined treatment had no significant improvement in the long-term survival of patients with advanced ovarian cancer.
作者
曹美婷
耿海燕
贾海霞
孙立新
CAO Meiting;GENG Haiyan;JIA Haixia;SUN Lixin(The Second Department of Gynecology,Shanxi Cancer Hospital,Taiyuan,030001,Shanxi,China;Department of Prevention and Health Care,Shanxi Cancer Hospital,Taiyuan,030001,Shanxi,China)
出处
《肿瘤药学》
CAS
2022年第4期508-513,共6页
Anti-Tumor Pharmacy
关键词
新辅助化疗
细胞减灭术
晚期
卵巢癌
疗效
Neoadjuvant chemotherapy
Cytoreductive surgery
Advanced
Ovarian cancer
Curative effect
